company background image
SPL logo

Starpharma Holdings ASX:SPL Stock Report

Last Price

AU$0.13

Market Cap

AU$51.5m

7D

0%

1Y

-73.1%

Updated

28 Mar, 2024

Data

Company Financials

Starpharma Holdings Limited

ASX:SPL Stock Report

Market Cap: AU$51.5m

SPL Stock Overview

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide.

SPL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Starpharma Holdings Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Starpharma Holdings
Historical stock prices
Current Share PriceAU$0.13
52 Week HighAU$0.53
52 Week LowAU$0.12
Beta0.82
1 Month Change-3.85%
3 Month Change-26.47%
1 Year Change-73.12%
3 Year Change-93.90%
5 Year Change-88.69%
Change since IPO-84.38%

Recent News & Updates

Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?

Dec 18
Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?

Recent updates

Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?

Dec 18
Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?

We Think Some Shareholders May Hesitate To Increase Starpharma Holdings Limited's (ASX:SPL) CEO Compensation

Nov 22
We Think Some Shareholders May Hesitate To Increase Starpharma Holdings Limited's (ASX:SPL) CEO Compensation

Here's Why Starpharma Holdings (ASX:SPL) Can Manage Its Debt Despite Losing Money

Mar 21
Here's Why Starpharma Holdings (ASX:SPL) Can Manage Its Debt Despite Losing Money

We're Hopeful That Starpharma Holdings (ASX:SPL) Will Use Its Cash Wisely

Jan 26
We're Hopeful That Starpharma Holdings (ASX:SPL) Will Use Its Cash Wisely

We Think Starpharma Holdings (ASX:SPL) Can Afford To Drive Business Growth

Jun 21
We Think Starpharma Holdings (ASX:SPL) Can Afford To Drive Business Growth

Starpharma Holdings Limited (ASX:SPL): Is Breakeven Near?

May 16
Starpharma Holdings Limited (ASX:SPL): Is Breakeven Near?

Here's Why We're Not At All Concerned With Starpharma Holdings' (ASX:SPL) Cash Burn Situation

Mar 02
Here's Why We're Not At All Concerned With Starpharma Holdings' (ASX:SPL) Cash Burn Situation

Is There An Opportunity With Starpharma Holdings Limited's (ASX:SPL) 27% Undervaluation?

Feb 10
Is There An Opportunity With Starpharma Holdings Limited's (ASX:SPL) 27% Undervaluation?

Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Jan 20
Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Did You Miss Starpharma Holdings' (ASX:SPL) Impressive 105% Share Price Gain?

Dec 28
Did You Miss Starpharma Holdings' (ASX:SPL) Impressive 105% Share Price Gain?

How Does Starpharma Holdings' (ASX:SPL) CEO Salary Compare to Peers?

Dec 07
How Does Starpharma Holdings' (ASX:SPL) CEO Salary Compare to Peers?

Shareholder Returns

SPLAU PharmaceuticalsAU Market
7D0%1.1%1.5%
1Y-73.1%44.7%11.6%

Return vs Industry: SPL underperformed the Australian Pharmaceuticals industry which returned 44.7% over the past year.

Return vs Market: SPL underperformed the Australian Market which returned 11.6% over the past year.

Price Volatility

Is SPL's price volatile compared to industry and market?
SPL volatility
SPL Average Weekly Movement10.1%
Pharmaceuticals Industry Average Movement10.6%
Market Average Movement8.7%
10% most volatile stocks in AU Market17.1%
10% least volatile stocks in AU Market3.2%

Stable Share Price: SPL's share price has been volatile over the past 3 months.

Volatility Over Time: SPL's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199745Cheryl Maleyhttps://starpharma.com

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers.

Starpharma Holdings Limited Fundamentals Summary

How do Starpharma Holdings's earnings and revenue compare to its market cap?
SPL fundamental statistics
Market capAU$51.51m
Earnings (TTM)-AU$8.39m
Revenue (TTM)AU$10.52m

4.9x

P/S Ratio

-6.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SPL income statement (TTM)
RevenueAU$10.52m
Cost of RevenueAU$11.68m
Gross Profit-AU$1.16m
Other ExpensesAU$7.24m
Earnings-AU$8.39m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.02
Gross Margin-11.02%
Net Profit Margin-79.79%
Debt/Equity Ratio0%

How did SPL perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.